Nutex Health Revenue Falls 18.7% to $217.6 Million in Third Quarter
Key Facts
Nutex Health reported results on November 5 for the third quarter ended September 30, 2026, recording revenue of $217.6 million, down 18.7% from the same period last year. Net income attributable to the company was $40.2 million, or $5.71 per diluted share, compared with $55.4 million and $7.76 per share a year earlier. Investing.com said earnings per share fell short of analysts’ estimate of $5.96, while revenue topped the consensus estimate of $214.12 million. The company reported results for the three and nine months ended September 30. The figures highlight a gap between increased hospital activity and lower quarterly revenue and profitability.
Hospital department visits rose 18.1% year over year to 54,622 in the quarter, while visits at same-hospital facilities increased 12.4%. But hospital revenue fell 20.1%, alongside a decline in total department revenue to $209.1 million from $260.2 million in the comparable period. The company said the increase in visits did not prevent a decline in revenue generated by its hospitals. By contrast, Population Health Management department revenue rose to $8.5 million from $7.6 million. The department remained much smaller than the hospital department in quarterly revenue.
The company attributed part of the revenue decline to additional collection data that supported higher estimates for revenue from services provided in 2024. It also cited the resolution of ineligible claims during the fourth quarter of 2025 that had previously been recorded. These factors put the year-over-year comparison in the context of adjustments related to revenue estimates and claims resolution. Arbitration costs totaled $27.8 million in the third quarter, compared with $41.9 million a year earlier. For the nine months ended September 30, those costs fell to $61.4 million from $116.2 million.
For the first nine months of 2026, revenue was $644.9 million, down 10.9% from $723.6 million in the same period of 2025. Net income attributable to the company rose to $152.9 million from $59.0 million. The nine-month results included a non-cash reduction of $52.3 million in contractual services expense. The company said the estimate adjustment increased net income attributable to it by $25 million, or $4.83 per diluted share. The nine-month income picture therefore differs from the quarterly comparison, with a clear effect from the estimate adjustment disclosed by the company.
Net cash generated from operating activities was $188.1 million in the first nine months, compared with $177.7 million a year earlier. As of September 30, cash and cash equivalents totaled $249.9 million, while long-term debt was $34.2 million. In trading, NUTX closed at $205.22 on November 4 and then at $193.64 on November 5, the day the results were published. An Investing.com report published on November 5 said the stock had risen 19.48% over the previous three months and 59.06% over 12 months. These figures provide a picture of the stock’s performance around the announcement, alongside liquidity and cash flow indicators for the period.
In broader context, the company said in its second-quarter report that hospital department revenue fell 14.6% year over year despite an increase in visits at the time. It attributed the decline mainly to positive variable consideration adjustments recognized in 2025, alongside early success in the independent dispute resolution process. The company expected to open two new hospitals in the fourth quarter of 2026, according to its chief financial officer. It also scheduled an earnings call for November 6 at 9:30 a.m. Central time. The call will give the company an opportunity to discuss results and its plans to open the two hospitals in the remaining quarter of the year.